Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2765)	4/13/2010 12:08:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ARRY was up 10.10% earlier and is still up 4.33% at present with volume of 433Ks already > its ADV. The stock has already closed its Dec15 UG.<g> bigcharts.marketwatch.com ARRY will be presenting eight abstracts at the AACR Annual Meeting, in Washington, DC later this week. It plans to disclose new findings about its anti-cancer programs: ARRY-162, ARRY-543, AZD6244 or ARRY-886 and three emerging programs for RAF, Chk1 and mTor inhibition. All posters and presentations will be available in PDF, after they are presented, on ARRY's website. The ACTAY is $5.66 and of course, the nearest resistance is the Dec15 H at $3.11 I think that with some good news the stock will be able to close its Sep4 DG and get back to the $4 level.<g> bigcharts.marketwatch.com The stock needs to close above $4 in order to get off from its longer term DT coming from the April 2007 H at $14.59 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2765)	4/16/2011 10:59:51 PM
From: Jibacoa	Respond to of 3722

OPXA was able to close most of its FEB DG albeit the price at the end of the day was closer to the intraday L than to the H.<g> However, trading volume was about the same as at the time of the FEB DG. bigcharts.marketwatch.com As mentioned, OPXA had a poster presentation at the AAN annual meeting in TX. The ACTAY is 6 but the stock has a good amount of resistance from the $2.25 to the $2.75 level. OPXA will need some good news in order to go through that resistance, but after that, it has plenty of room to run.<g> bigcharts.marketwatch.com Bernard